Ritter Pharmaceuticals Inc (RTTR) Downgraded to Sell at Zacks Investment Research

ritter-pharmaceuticals-inc-rttr-downgraded-to-sell-at-zacks-investment-research.jpg

Ritter Pharmaceuticals Inc (NASDAQ:RTTR) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Wednesday.
According to Zacks, “Ritter Pharmaceuticals, Inc. is involved in developing therapeutic products to treat inflammatory, gastrointestinal and metabolic diseases. Its lead product candidate is RP-G28, a novel microbiome modulator, which is under development for the reduction of symptoms associated with lactose intolerance. Ritter Pharmaceuticals, Inc. is headquartered in Los Angeles, California. “
Separately, Maxim Group reaffirmed a “buy” rating on shares of Ritter Pharmaceuticals in a research report on Wednesday, June 22nd.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/17/ritter-pharmaceuticals-inc-rttr-downgraded-to-sell-at-zacks-investment-research.html

Ritter Pharmaceuticals (NASDAQ:RTTR) traded up 9.56% on Wednesday, hitting $1.49. The stock had a trading volume of 90,323 shares. Ritter Pharmaceuticals has a 52 week low of $0.98 and a 52 week high of $3.39. The stock’s market capitalization is $12.79 million. The company has a 50-day moving average price of $1.34 and a 200-day moving average price of $1.49.
Ritter Pharmaceuticals (NASDAQ:RTTR) last announced its earnings results on Monday, August 8th. The company reported ($0.48) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.34) by $0.14. Equities research analysts anticipate that Ritter Pharmaceuticals will post ($1.38) earnings per share for the current fiscal year.
Ritter Pharmaceuticals Company Profile
Ritter Pharmaceuticals, Inc develops therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. The Company’s segment is focusing on the development and commercialization of RP-G28. The Company conducts human gut health research by exploring metabolic capacity of the gut microbiota and translating the functionality of prebiotic-based therapeutics into applications intended to have impact on a patient’s health.

Get a free copy of the Zacks research report on Ritter Pharmaceuticals (RTTR)
For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Ritter Pharmaceuticals Inc Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Ritter Pharmaceuticals Inc and related companies with MarketBeat.com’s FREE daily email newsletter.

Be the first to comment on "Ritter Pharmaceuticals Inc (RTTR) Downgraded to Sell at Zacks Investment Research"

Leave a comment

Your email address will not be published.

*